Eagle Pharmaceuticals, Inc. is a biotechnology pharmaceutical company, which focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company is headquartered in Woodcliff Lake, New Jersey and currently employs 134 full-time employees. The company went IPO on 2014-02-12. The firm is focused on developing medicines that result in improvements in patients' lives. The firm's commercialized products include vasopressin, PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO and BARHEMSYS through its wholly owned subsidiary Acacia Pharma Inc. Its oncology and central nervous system (CNS)/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. The firm also has a research and development facility in Cambridge, Massachusetts. The firm is also focused on developing medicines with the potential to become part of the personalized medicine paradigm in cancer care. The firm has office space in Palm Beach Gardens, Florida and Indianapolis, Indiana.
Follow-Up Questions
Eagle Pharmaceuticals Inc (EGRX)의 PER은 얼마입니까?
Eagle Pharmaceuticals Inc의 PER은 1.3589입니다
EGRX 주식의 가격 성능은 어떻습니까?
EGRX의 현재 가격은 $3.06이며, 전 거래일에 decreased 0% 하였습니다.
Eagle Pharmaceuticals Inc의 주요 사업 주제나 업종은 무엇입니까?
Eagle Pharmaceuticals Inc은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
Eagle Pharmaceuticals Inc의 시가총액은 얼마입니까?
Eagle Pharmaceuticals Inc의 현재 시가총액은 $39.7M입니다
Eagle Pharmaceuticals Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 3명의 분석가가 Eagle Pharmaceuticals Inc에 대한 분석 평가를 실시했으며, 이는 3명의 강력한 매수, 3명의 매수, 1명의 보유, 0명의 매도, 그리고 3명의 강력한 매도를 포함합니다